UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Méthodes diagnostiques et stratégie thérapeutique des TNE pulmonaires (tumeurs carcinoïdes typiques et atypiques)

Oncologie (Paris, France), 2020, Vol.21 (5-12), p.83

Dansin, E.

2020

Volltextzugriff (PDF)

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Annals of oncology, 2016-02, Vol.27 (2), p.281-286

2016

Volltextzugriff (PDF)

The future: surgical advances in MEN1 therapeutic approaches and management strategies

Endocrine-related cancer, 2017-10, Vol.24 (10), p.T243-T260

2017

Volltextzugriff (PDF)

Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations

Annals of oncology, 2018-10, Vol.29, p.viii541-viii541

2018

Volltextzugriff (PDF)

Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France: Final results of the AVANTAGE study

Annals of oncology, 2018-10, Vol.29, p.viii518-viii518

2018

Volltextzugriff (PDF)

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort

ESMO open, 2024-06, Vol.9 (6), p.103473, Article 103473

2024

Volltextzugriff (PDF)

3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience

European journal of cancer (1990), 2015-09, Vol.51, p.S616-S617

2015

Volltextzugriff (PDF)

MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer

Revue des maladies respiratoires, 2018-10, Vol.35 (8), p.796

2018

Volltextzugriff (PDF)

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences

Cell death & disease, 2015-05, Vol.6 (5), p.e1769-e1769

2015

Volltextzugriff (PDF)

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

The European respiratory journal, 2012-01, Vol.39 (1), p.172-179

2012

Volltextzugriff (PDF)

3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort

European journal of cancer (1990), 2015-09, Vol.51, p.S646-S646

2015

Volltextzugriff (PDF)

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.231-236

2014

Volltextzugriff (PDF)

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care

British journal of cancer, 2010-04, Vol.102 (8), p.1207-1212

2010

Volltextzugriff (PDF)

Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study

Respiratory medicine and research, 2020-03, Vol.77, p.58-66

2020

Volltextzugriff (PDF)

Reflections on the limits of specific treatments in thoracic oncology

Revue des maladies respiratoires, 2015-02, Vol.32 (2), p.166

2015

Volltextzugriff (PDF)

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-12, Vol.34 (34), p.4079-4085

2016

Volltextzugriff (PDF)

Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors

Annals of oncology, 2010-08, Vol.21 (8), p.1682-1686

2010

Volltextzugriff (PDF)

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

The New England journal of medicine, 2014-12, Vol.371 (23), p.2167-2177

2014

Volltextzugriff (PDF)

Carcinomes neuroendocrines à grandes cellules (CNEGC) : actualités 2024

Revue des maladies respiratoires actualités, 2024-10, Vol.16 (2), p.2S250-2S254

2024

Volltextzugriff (PDF)

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-10, Vol.12 (10), p.1552-1560

2017

Volltextzugriff (PDF)

Évaluation, prévention et gestion des toxicités des inhibiteurs d’ALK et d’EGFR

Revue des maladies respiratoires actualités, 2018-10, Vol.10 (3), p.454-465

2018

Volltextzugriff (PDF)

75P STEREOTACTIC RADIOTHERAPY FOR LUNG CANCER: EARLY EFFICACY AND TOXICITY EVALUATION OF A NON-INVASIVE REAL-TIME TUMOR TRACKING SYSTEM

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S38-S39

2011

Volltextzugriff (PDF)

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma

Annals of oncology, 2010-06, Vol.21 (6), p.1385-1387

2010

Volltextzugriff (PDF)

Anti-Hu antibody syndrome: diagnostic and therapeutic difficulties

Revue des maladies respiratoires, 2013-09, Vol.30 (7), p.563

2013

Volltextzugriff (PDF)

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

Endocrine-related cancer, 2024-09, Vol.31 (9)

2024

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(175)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Französisch
(92)
Englisch
(91)

Erscheinungsjahr

n.n

Thema

Humans
(40)
Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Female
(26)
Male
(24)
Middle Aged
(23)
Aged
(21)
Oncology
(20)
Sciences Biologiques Et Medicales
(19)
Sciences Medicales
(19)
Lung Neoplasms - Drug Therapy
(17)
Respiratory System
(16)
Adult
(15)
Lung Cancer
(15)
Pneumologie
(14)
Biological And Medical Sciences
(13)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Medical Sciences
(13)
Lung Neoplasms - Pathology
(11)
Tumeurs De L'appareil Respiratoire Et Du Médiastin
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Méthodes diagnostiques et stratégie thérapeutique des TNE pulmonaires (tumeurs carcinoïdes typiques et atypiques)

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

The future: surgical advances in MEN1 therapeutic approaches and management strategies

Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations

Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France: Final results of the AVANTAGE study

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort

3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience

MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care

Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study

Reflections on the limits of specific treatments in thoracic oncology

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer

Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Carcinomes neuroendocrines à grandes cellules (CNEGC) : actualités 2024

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

Évaluation, prévention et gestion des toxicités des inhibiteurs d’ALK et d’EGFR

75P STEREOTACTIC RADIOTHERAPY FOR LUNG CANCER: EARLY EFFICACY AND TOXICITY EVALUATION OF A NON-INVASIVE REAL-TIME TUMOR TRACKING SYSTEM

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma

Anti-Hu antibody syndrome: diagnostic and therapeutic difficulties

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

Suchergebnisse filtern